CLOs on the Move

Curaleaf

www.curaleaf.com

 
Curaleaf (CSE: CURA) is a leading vertically integrated cannabis operator in the United States. Headquartered in Wakefield, Massachusetts, Curaleaf is located in 10 states and owns and operates 26 dispensaries, 10 cultivation sites and 9 processing sites with a focus on highly populated, limited license states, including Florida, Massachusetts, New Jersey and New York. Here at Curaleaf, we leverage our extensive research and development capabilities to distribute cannabis products in multiple formats with the highest standard for safety, effectiveness, consistent quality and customer care. We are committed to being the industry`s leading resource in education and advancement through research and ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.curaleaf.com
  • 301 Edgewater Place Suite 405
    Wakefield, MA USA 01880
  • Phone: 781.451.0150

Executives

Name Title Contact Details
Cristina Nutzman
 Vice President, Legal-Labor and Employment Profile
Kyle Crossley
 Assistant General Counsel and Corporate Secretary Profile
Troy Morgan
 Senior Vice President of Compliance Profile
Peter Clateman
 Executive Vice President of Business Development Profile
Todd Goffman
 General Counsel Profile

Similar Companies

CMC ICOS Biologics Inc.

CMC ICOS Biologics Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Bothell, WA. To find more information about CMC ICOS Biologics Inc., please visit www.cmcbio.com

BMR HealthQuest

BMR HealthQuest is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Apollo Light Systems

Apollo Light Systems is a Orem, UT-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Quantum Group

Quantum Group is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Quantum Group is based in Wellington, FL. You can find more information on Quantum Group at www.quantummd.com

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.